Difference between revisions of "CT Angiography Biomarker Ctte"
Line 23: | Line 23: | ||
==Profile Development== | ==Profile Development== | ||
− | *[[Media:Atherosclerosis_Biomarkers_Profile_Jun2024.pdf|CT Atherosclerosis Biomarkers, Clinically Feasible Profile: | + | *[[Media:Atherosclerosis_Biomarkers_Profile_Jun2024.pdf|''CT Atherosclerosis Biomarkers, Clinically Feasible Profile: Maintenance draft (June, 2024)'' <b>DOI:10.1148/QIBA/202406</b>]]</td nowrap> |
*[[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf|'''CT Atherosclerosis Biomarkers, Clinically Feasible Profile. (March 28, 2023)''' <b>DOI:10.1148/QIBA/20230328</b>]] | *[[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf|'''CT Atherosclerosis Biomarkers, Clinically Feasible Profile. (March 28, 2023)''' <b>DOI:10.1148/QIBA/20230328</b>]] | ||
*[[Media:QIBA CTA Profile as of 2023-Feb-16.pdf|QIBA Atherosclerosis Biomarkers Profile Draft]] | *[[Media:QIBA CTA Profile as of 2023-Feb-16.pdf|QIBA Atherosclerosis Biomarkers Profile Draft]] |
Latest revision as of 15:22, 11 July 2024
Co-chairs: Andrew Buckler, MS, PhD; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT
Meetings
Recent Call Summaries:
CT Angiography Call Summaries Archive
Project Snapshot - CT Angiography
The group intends to pursue writing quantitative profiles for both Coronary computed tomography angiography (CCTA) and CT angiography (CTA).
Excerpt from the biomarker committee submission form:
The QIBA Atherosclerosis Biomarkers Committee (ABC) is organized to document quantitative profiles for both Computed Tomography Angiography (CTA) and Coronary CTA (CCTA). The membership is composed of participants from multiple centers of excellence within North America and Europe utilizing different CTA vendors, acquisitions and scanner types, and analysis software vendors. Representatives from different manufacturers are included in the committee, who are interested in working closely with the committee in optimizing imaging biomarkers for scientific trials and clinical routine use. The Biomarker Committee develops technical performance standards to serve as atherosclerosis compositional biomarkers, engaging stakeholders from different societies, in addition to the RSNA, for example ASNR, SCCT, ACR, etc.
Profile Development
- CT Atherosclerosis Biomarkers, Clinically Feasible Profile: Maintenance draft (June, 2024) DOI:10.1148/QIBA/202406
- CT Atherosclerosis Biomarkers, Clinically Feasible Profile. (March 28, 2023) DOI:10.1148/QIBA/20230328
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Checklists
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft (reduced page count)
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft
Atherosclerosis Biomarkers Profile Draft Archive
Groundwork Projects
Reference Materials
- QIBA Biomarkers Selection Criteria Atherosclerosis Biomarker Committee (ABC) {Mr. Buckler} March 27, 2018 (PDF)